Upstream Bio Inc. (UPB)
| Bid | 8.64 |
| Market Cap | 466.55M |
| Revenue (ttm) | 2.29M |
| Net Income (ttm) | -52.17M |
| EPS (ttm) | -5.58 |
| PE Ratio (ttm) | -1.56 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 10.58 |
| Volume | 432,967 |
| Avg. Volume (20D) | 268,330 |
| Open | 9.11 |
| Previous Close | 9.00 |
| Day's Range | 8.68 - 9.29 |
| 52-Week Range | 5.14 - 29.46 |
| Beta | 0.10 |
About UPB
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in ...
Analyst Forecast
According to 4 analyst ratings, the average rating for UPB stock is "Buy." The 12-month stock price forecast is $56.5, which is an increase of 550.17% from the latest price.
Stock Forecasts
2 weeks ago · seekingalpha.com
Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is ImminentUpstream Bio's IPO raised ~$293m, focusing on developing verekitug, a unique TSLP receptor antagonist for severe respiratory disorders, now in Phase 2 trials. The company has a strong cash position of...